Effect of ASCO/CAP guidelines for determining ER status on molecular subtype

Annals of Surgical Oncology

Volumn 20, Issue 1, 2013, Pages 87-93

  Deyarmin, Brenda ^a   Kane, Jennifer L ^a   Valente, Allyson L ^a   Van Laar, Ryan ^b   Gallagher, Christopher ^c   Shriver, Craig D ^c   Ellsworth, Rachel E ^d  

^a WINDBER RESEARCH INSTITUTE   (United States)

^b ChipDX LLC   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d Henry M Jackson Foundation for the Advancement of Military Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ACCURACY; ADULT; ARTICLE; BREAST CARCINOMA; CANCER STAGING; CANCER SURGERY; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PARTIAL MASTECTOMY; PRACTICE GUIDELINE; PROTEIN EXPRESSION;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RNA; TREATMENT OUTCOME;

EID: 84871762532     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2588-8     Document Type: Article

References (26)

1. Pietras RJ, Marquez-Garban DC. Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res. 2007;13:4672-6.
2. Aaltomaa S, Lipponen P, Eskelinen M, et al. Hormone receptors as prognostic factors in female breast cancer. Ann Med. 1991;23(6):643-8.
3. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9:R6.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451-67.
5. Regan MM, Viale G, Mastropasqua MG, et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006;98(21):1571-81.
6. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1998;51:227-38.
7. Engel KB, Moore HM. Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med. 2011;135:537-43.
8. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16(10):1569-83.
9. Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784-95.
10. American Joint Committee on Cancer. AJCC Cancer Staging Manual, 7th ed. New York: Springer; 2010.
11. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer. 1957;11:359-77.
12. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology. 1991;19:403-10.
13. van Laar R. Design and multiseries validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival. J Mol Diagn. 2011;13(3):297-304.
14. Sabatier R, Finetti P, Cervera N, et al. A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat. 2011;126(2):407-20.
15. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52.
16. Sorlie T, Perou CM, Tibshirania R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869-74.
17. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271-7.
18. Raghav KPS, Hernandez-Aya LF, Lei X, et al. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer. 2012;118(6):1498-506.
19. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26:3785-90.
20. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123-34.
21. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364(3):205-14.
22. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235-44.
23. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852-61.
24. Paik S. Is gene array testing to be considered routine now? Breast. 2011;20(Suppl 3):S87-91.
25. Ellis MJ, Ding L, Shen, D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibitors. Nature. 2012; 486(7403):353-60.
26. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295(21): 2492-502.